www.dailypolitical.com ·
Praxis Precision Medicines Nasdaqprax Issues Earnings Results
Topic context
This topic has been covered 379197 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedPraxis Precision Medicines is a biotech firm with two NDAs under FDA review. The commercial mechanism is regulatory: PDUFA dates create binary catalysts for revenue potential if approved. The EMERALD study results could expand addressable patient population. No immediate supply chain or scarcity impact; impact is company-specific and binary.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Praxis Precision Medicines reported Q1 EPS of ($3.20), beating estimates of ($3.58).
- NDAs accepted for ulixacaltamide and relutrigine with PDUFA dates Jan 29 and Sep 27.
- EMERALD study enrollment completed; top-line results expected Q4, potentially expanding relutrigine market to ~200,000 US patients.
- Q1 operating expenses ~$106 million; cash balance $1.4 billion after January offering.
- Stock closed down 1.4% at $333.28, market cap $9.29 billion.
Praxis Precision Medicines stock is expected to remain flat in the short term following Q1 EPS beat and NDA acceptance; magnitude 2.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHmid
- PHARMA_BIOTECHshort
Related stories
finance.yahoo.com
Ncmi Q1 2026 Earnings Transcript
finance.yahoo.com
Transcript Valneva Q1 2026 Earnings
fool.com
Keysight Keys Q2 2026 Earnings Transcript
livemint.com
Haryana Bars Petrol Diesel Cabs for Aggregators What Means Pm Modis Austerity Push Ncrs Aqi Fuel News
economictimes.indiatimes.com